Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial
JAMA Internal Medicine
•
February 02, 2026
Oral semaglutide reduced heart-failure events
In people with type 2 diabetes and existing heart failure, oral semaglutide lowered a combined risk of heart-failure worsening or cardiovascular death without more serious side effects. *Secondary analysis of randomized clinical trial; Level 2b (OCEBM).
- Level of evidence
- Level 2b (OCEBM)
- DocG quality score
- 7.2 / 10
Read the full summary free
Patients, intervention, outcomes, results, and clinical applicability in about 300 words — plus new summaries in your inbox 3× per week.
Sign in with Google
